Abivax SA（ABVX）資訊與事件

$111.730

-1.598 (-1.43%)收盤時

ABVX 資訊

9.008-04Yahoo Finance

Evexta Bio Partners with Roche for Breast Cancer Clinical Trial

8.507-30Newsfilter

Abivax Announces Positive Pre-NDA Interaction with FDA for Obefazimod

8.507-30Newsfilter

Abivax Annual Meeting Highlights and Future Outlook

8.507-10CNBC

Abivax Secures Funding for U.S. Drug Launch Amid Takeover Speculation

8.507-10Newsfilter

Abivax Secures Funding for U.S. Drug Launch Without Big Pharma Support

8.507-08Fool

Three High-Potential Stocks: Abivax, Krystal Biotech, and Marvell

8.507-08NASDAQ.COM

Abivax, Krystal Biotech, and Marvell's Market Potential

8.507-02seekingalpha

Abivax Completes $920M Public Offering with Full Underwriter Option Exercise

8.507-02stocktwits

Abivax Increases Offering to 7.36 Million Shares, Raising $874.1 Million

8.507-02Newsfilter

Abivax Fully Exercises Underwriters' Option for Additional ADS Purchase

查看更多資訊

ABVX 事件

7/30 17:30

Abivax Completes Positive FDA Interaction, Plans NDA Submission by 2026

Abivax announced the successful completion of its positive pre-New Drug Application interaction with the U.S. Food and Drug Administration for obefazimod for the treatment of adults with moderately to severely active ulcerative colitis. Constructive FDA feedback resulted in alignment on the company's planned NDA submission strategy and supported the planned content and format of the NDA submission. Abivax remains on track to submit its first NDA for obefazimod by the end of 2026.

7/17 14:30

Abivax Secures €800M Funding, Suspends Takeover Talks

Marc de Garidel's company suspended takeover talks with pharma giants including AstraZeneca (AZN) and Eli Lilly (LLY) last month as it secured an EUR 800M capital raise. Its new funding gives Abivax (ABVX) the luxury of entering any takeover negotiations from a position of strength, La Lettre's Matthieu Protard reports.

7/1 09:30

Increased Deal Size to $800M in Common Stock

The deal size was increased to $800M in common stock from $600M in common stock. Leerink, Morgan Stanley, Piper Sandler and Guggenheim acted as joint book running managers for the offering.

7/1 08:30

Leerink, Morgan Stanley, and Others Jointly Manage Offering

Leerink, Morgan Stanley, Piper Sandler and Guggenheim acted as joint book running managers for the offering.

6/30 17:30

Leerink, Morgan Stanley, and Others Jointly Manage New Stock Offering

Leerink, Morgan Stanley, Piper Sandler and Guggenheim are acting as joint book running managers for the offering.

查看更多事件

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。